Indeed, it has been demonstrated that PXR is able to contribute to chemotherapy resistance in many types of cancer, e.g., colon, breast, and prostate cancer, since its activation regulates transcription of chemoresistance-related genes, such as drug-metabolizing enzymes (e.g., CYP3A4) and transporters (P-glycoprotein and other multidrug resistance proteins) [95,96]. The gene discussed is NR1I2; the disease is cancer.